Congress must protect the research behind tomorrow's cures

The article warns that America's biomedical research leadership is diminishing as drug development and production shift overseas, especially to China, raising significant patient safety concerns due to weaker regulatory standards. It calls on Congress to ensure that research validation remains rigorous and that incentives keep biomedical research and manufacturing in the U.S.

This Wire brief sits within Fusion42's coverage of Biotech.